This directory serves as a resource listing of active biotech that develop therapeutics, diagnostics and/or medtech. The companies listed in this directory are not representative of the companies that are active members of the Biotech and Money community.
Add / Amend your company listing for free
(only active biotech ie. therapeutic, diagnostic and medtech companies are eligible for listing)
The lead drug candidate, AKR 202, is scheduled to enter a phase IIa proof-of-concept study in pain associated with osteoarthritis, having already obtained a regulatory ?thumbs up? from a BfArM scientific advice meeting, with first-patient-in in Q4?13. Top-line data is expected Q4'14.
AKR 202 can be administered once daily orally, and has a favourable short and long-term clinical safety profile also when compared to current pain therapies. AKR 202 showed analgesic efficacy across a range of different rodent models of pain, coupled with anti-inflammatory and potentially disease-modifying effects. AKR 202 represents a novel mechanism of action for the treatment of pain, with a potential for first-in-class status.
Further fields of research and development include food diagnostics and quality control products for the pharmaceutical industry.
Their novel GENSPEED